Coronary Scoring Balloons Market By Balloon Type (Semi-Compliant Scoring Balloons, Non-Compliant Scoring Balloons), By Lesion Type (Calcified Lesions, Fibrotic Lesions, In-Stent Restenosis, Ostial and Bifurcation Lesions, Other Complex Coronary Lesions), By End User (Hospitals, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers, Specialty Cardiac Clinics), By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Coronary Scoring Balloons Market: Complex Lesion Preparation and DCB Adoption Reshape Demand

The Global Coronary Scoring Balloons Market was valued at USD 160 million in 2025 and is projected to reach USD 270 million by 2032, expanding at a CAGR of 7.8% during 2026–2032, according to internal projections by Strategic Market Research. This represents an absolute revenue increase of USD 110 million and cumulative growth of 68.8% across the forecast period.

 

Coronary scoring-balloon treatment currently includes FDA-approved devices such as AngioSculpt Evo, Scoreflex NC and Lacrosse NSE Alpha for preparing calcified or fibrotic lesions, treating in-stent restenosis and supporting drug-coated balloon procedures. Their external nitinol or wire-based elements apply focused pressure to resistant tissue while reducing balloon slippage, allowing more controlled vessel expansion than conventional balloons in selected complex lesions. These differences have made the market increasingly segmented by lesion calcification, prior stent status, vessel anatomy and the intended follow-on treatment rather than by overall PCI volume alone.

 

The coronary scoring balloons market is growing due to rising treatment of complex coronary artery disease, particularly calcified and previously stented vessels where standard balloons are often inadequate. With moderate-to-severe calcification present in about 25%–30% of PCI patients, guidelines recommend scoring or cutting balloons when initial dilation is insufficient, while reserving advanced tools like lithotripsy or atherectomy for more severe cases. Market demand is further supported by over 461,000 U.S. inpatient cases and around 94,000 UK procedures annually. Applying the calcification range to U.S. inpatient volume indicates a theoretical pool of approximately 115,000–138,000 complex cases.

 

Expanding Role of Scoring Balloons in Complex Coronary Interventions

Stent performance depends heavily on adequate lesion preparation before implantation. Severe coronary calcification can prevent uniform stent expansion, leading to underexpanded segments that are associated with higher risks of thrombosis and restenosis. Scoring balloons address this challenge by applying focused, controlled force through external scoring elements, enabling plaque modification at lower inflation pressures compared to conventional non-compliant balloons.

In clinical practice, scoring balloons are used as one of several lesion-preparation tools alongside standard balloons, cutting balloons, atherectomy, and intravascular lithotripsy. They are often selected when a lesion is resistant to conventional balloon dilation but does not require more aggressive plaque modification techniques. In some cases, they are also used after calcium modification procedures to achieve more uniform and controlled vessel expansion, extending their role across different stages of complex PCI.

Their use is particularly relevant in anatomically challenging segments such as proximal, distal, ostial, and tortuous coronary arteries. In these settings, device deliverability becomes an important consideration alongside scoring efficiency, since the balloon must successfully cross the lesion before any modification can occur. As a result, design features such as low crossing profiles, flexible shafts, hydrophilic coatings, and a broad size matrix can influence physician preference and hospital procurement decisions.

 

In-Stent Restenosis Creates a Recurring Procedure Market

In-stent restenosis remains another important application because the treatment site already contains a permanent metal structure and newly formed tissue. It accounts for roughly 10% of U.S. PCI procedures, creating a recurring intervention pool rather than demand limited to newly diagnosed lesions. Ordinary balloons may slip away during inflation, commonly described as the “watermelon seed effect.” External scoring elements help grip the treatment area, reducing unwanted movement and limiting injury outside the intended segment.

The FDA-approved indications of leading devices confirm the commercial importance of this application. AngioSculpt received U.S. approval in 2007 for significant coronary stenosis, including in-stent restenosis and complex Type C lesions. Scoreflex NC received approval in December 2021 for both newly formed stenosis and coronary in-stent restenosis. These indications allow manufacturers to compete across initial and repeat procedures.

Restenosis is increasingly being managed with drug-coated balloon (DCB) therapy, particularly in patients where avoiding an additional permanent stent is preferred. DCBs deliver an antiproliferative drug to the vessel wall without leaving behind a metal scaffold. However, adequate lesion preparation is essential before drug delivery, as restenotic segments must be uniformly expanded and residual stenosis minimized. In this context, scoring balloons are often used to improve lesion compliance and facilitate controlled expansion in resistant or fibrotic restenotic tissue.

Evidence from the U.S. CathPCI Registry indicates a growing integration of DCB therapy into real-world PCI practice. Between April 2024 and June 2025, 14,946 coronary DCBs were used in 12,337 patients across 704 hospitals. Reported DCB use in in-stent restenosis increased from less than 1% to 17.5% over the study period. Specialty cutting or scoring balloons were used in 45.3% of DCB cases, compared with 17.5% in drug-eluting stent procedures, suggesting that lesion preparation devices are more frequently adopted when DCB therapy is selected. Based on reported volumes, this corresponds to approximately 6,770 DCB procedures involving adjunctive specialty balloons.

Registry data from the United Kingdom similarly reflects increasing adoption of balloon-based revascularization strategies. Drug-coated balloons accounted for approximately 13% of PCI activity in 2023–2024, rising from low single-digit levels in prior years. This trend suggests broader clinical acceptance of DCB therapy, although actual device selection varies by lesion complexity, operator preference, and institutional protocols.

However, increased DCB adoption does not imply universal replacement of repeat stenting in restenosis cases. Evidence from pooled randomized trials suggests that both DCBs and repeat drug-eluting stenting can achieve comparable outcomes in selected in-stent restenosis populations, with differences depending on lesion type, stent generation, and patient risk profile. Therefore, the extent to which DCB growth translates into incremental demand for scoring balloons will depend on how frequently operators choose DCB-based strategies over alternative revascularization approaches.

 

Competition Across Calcium-Modification and Lesion Preparation Technologies

Coronary scoring-balloon suppliers compete primarily with cutting balloons and high-pressure non-compliant balloons in lesion preparation, while the broader competitive landscape includes atherectomy and intravascular lithotripsy (IVL) systems. These technologies address the same clinical objective—modifying calcified or fibrotic plaque to enable optimal stent expansion—though they differ significantly in cost, procedural complexity, and lesion applicability.

Medtronic’s Wolverine cutting balloon competes in many of the same calcified and fibrotic lesion subsets, particularly where controlled plaque incision is required. Philips markets the AngioSculpt scoring balloon system, while OrbusNeich has developed a strong scoring-balloon portfolio through the Scoreflex platform.

Recent investment activity highlights the strategic importance of coronary calcium modification technologies. Johnson & Johnson completed its acquisition of Shockwave Medical in May 2024, strengthening its position in intravascular lithotripsy. This reflects growing interest among large medtech companies in expanding their calcium-modification toolkits across complex PCI.

Scoring-balloon systems are not intended to replace atherectomy or IVL in severely calcified lesions. Instead, their value lies in their simplicity, compatibility with standard balloon-based workflows, and effectiveness in moderate-to-intermediate calcification where more complex devices may not be required. As a result, manufacturers increasingly position scoring balloons as part of an integrated lesion-preparation strategy rather than a standalone universal solution, supporting broader adoption while maintaining procedural efficiency and clinical safety.

 

The United States Leads Adoption While Asia Adds Procedure Volume

The United States remains the most commercially attractive market because of high PCI activity, structured hospital purchasing and the recent rise of coronary DCB procedures. Strategic Market Research’s internal regional allocation places North America at approximately 38% of the 2025 market, equivalent to about USD 60.8 million. If this share remains broadly stable, regional revenue would approach USD 102.6 million by 2032, broadly tracking the global 7.8% CAGR. FDA approvals for AngioSculpt, Scoreflex NC and newer products have expanded competition while giving physicians multiple scoring designs for restenosis and difficult native lesions.

Europe has a longer history of DCB use and established clinical familiarity with scoring and cutting balloons. Adoption differs by country and hospital, creating opportunities for direct sales teams, physician education and distributor expansion rather than one uniform regional strategy.

Asia-Pacific combines high procedure volumes, domestic manufacturing and expanding regulatory approvals. OrbusNeich reported that total company revenue increased 10% to US$180.5 million in FY2025, while sales volume rose 16.2% to 2.02 million units. Revenue increased 37% in the United States, 19.6% in Europe, the Middle East and Africa, and 15.7% in Asia-Pacific.

These figures cover OrbusNeich’s broader interventional portfolio rather than scoring balloons alone, but they indicate regional coronary-device demand and the value of manufacturing scale under procurement pressure.

Pricing conditions will remain less favourable in markets using centralised or volume-based procurement. Increased unit demand can be accompanied by declining average selling prices, particularly in China. Manufacturers with efficient production, broad registration coverage and direct hospital access will be better positioned to protect margins than companies dependent on a small number of distributors or premium pricing.

 

Drug-Coated Balloon Growth Expands the Market Beyond Stent Preparation

Drug-coated balloon adoption is widening the role of scoring devices beyond conventional preparation for drug-eluting stents. In a stentless procedure, the artery must be adequately opened before the DCB is delivered because the drug-coated device is not intended to correct major residual narrowing or uncontrolled dissection.

Scoring balloons can create controlled lines in resistant tissue and improve expansion before drug delivery. Their ability to remain stable during inflation is particularly relevant in restenotic lesions, where smooth tissue inside an existing stent may cause ordinary balloons to move beyond the intended treatment zone.

The commercial relationship between the two device categories is visible in U.S. registry data, where scoring or cutting balloons were used in 45.3% of reported DCB procedures. This share was nearly 2.6 times the 17.5% utilisation recorded in drug-eluting-stent cases. Every increase in DCB-treated restenosis therefore creates a potential preparation-device sale, although the actual conversion rate depends on lesion complexity and physician practice.

The opportunity may broaden further as companies study DCB treatment in small vessels, bifurcations and selected newly formed lesions. However, manufacturers must avoid treating all DCB growth as automatic scoring-balloon demand. Some lesions can be prepared with standard non-compliant balloons, while severe calcium may require IVL or atherectomy.

 

Coronary Scoring Balloons Market Segmentation: Mapping Device Demand Across Lesion Complexity and Clinical Use Cases

Balloon Design Spectrum: Semi-Compliant vs Non-Compliant Scoring Technologies

Semi-compliant scoring balloons held the largest share of the market in 2025 at 58.0%, generating USD 92.8 million. This segment is expected to reach USD 145.8 million by 2032, though its share will slightly decline to 54.0% as non-compliant types grow faster. Products like AngioSculpt Evo and Lacrosse NSE Alpha support this segment due to their flexibility and ability to treat a wide range of calcified, fibrotic, and restenotic lesions.

Non-compliant scoring balloons accounted for 42.0% of the market in 2025, or USD 67.2 million, and are projected to grow to USD 124.2 million by 2032 at a faster CAGR of 9.2%. Their growth is driven by demand for stronger, more controlled expansion in heavily calcified lesions. Scoreflex NC is a key product in this category, supporting adoption in more complex coronary cases.

 

Lesion-Based Segmentation: Mapping Device Use Across Coronary Complexity Profiles

Calcified lesions were the largest segment in 2025, accounting for 44% of the market (USD 70.4 million) and are expected to reach USD 126.9 million by 2032 at an 8.8% CAGR. Growth is driven by increasing coronary calcium in older PCI patients, which makes vessel expansion and stent placement more difficult and increases the need for lesion-preparation tools like scoring balloons.

Fibrotic lesions held 19% share in 2025 (USD 30.4 million) and are projected to reach USD 48.6 million by 2032 at a 6.9% CAGR. These lesions are harder to dilate with standard balloons, supporting steady but slower growth.

In-stent restenosis accounted for 17% of the market (USD 27.2 million) and is expected to grow to USD 47.3 million by 2032 at an 8.2% CAGR. Demand is supported by increasing use of drug-coated balloons, where scoring balloons help stabilize and prepare the vessel before drug delivery.

Ostial and bifurcation lesions made up 12% of the market (USD 19.2 million) and are projected to reach USD 29.7 million by 2032 at a 6.4% CAGR, driven by the need for precise balloon positioning in complex vessel branches.

Other complex lesions accounted for 8% (USD 12.8 million) and are expected to reach USD 17.6 million by 2032 at a 4.6% CAGR, reflecting more variable and case-specific device use.

 

End-User Landscape: Where Coronary Scoring Balloons Are Actually Used in Practice

Hospitals remained the largest end-user in 2025, holding 56.0% share and USD 89.6 million in revenue. This is expected to rise to USD 143.1 million by 2032, though share will slightly ease to 53.0% as procedures gradually shift to more specialized settings. Hospitals continue to dominate complex PCI due to full emergency support, imaging systems, and access to advanced lesion-preparation tools.

Cardiac catheterization laboratories accounted for 28.0% of the market (USD 44.8 million) in 2025 and are projected to grow fastest, reaching USD 83.7 million by 2032 at a 9.3% CAGR. Their growth reflects increasing concentration of complex PCI and intravascular imaging in dedicated interventional centers.

Ambulatory surgical centers held 9.0% share (USD 14.4 million) in 2025 and are expected to reach USD 27.0 million by 2032, driven by a shift of lower-risk cardiovascular procedures to outpatient care. However, complex cases will still largely remain in hospitals.

Specialty cardiac clinics made up 7.0% of the market (USD 11.2 million) in 2025 and are projected to reach USD 16.2 million by 2032, growing steadily but limited by lower access to full emergency and interventional infrastructure.

 

Global Regional Demand Landscape and Growth Outlook

North America led the market in 2025 with a 40.0% share (USD 64.0 million), driven by strong PCI infrastructure, high procedure volumes, and early FDA approvals for scoring balloon devices. The region is expected to reach USD 99.9 million by 2032, though its share will slightly decline as Asia-Pacific grows faster.

Europe held 27.0% of the market (USD 43.2 million) in 2025 and is projected to reach USD 70.2 million by 2032. Growth is supported by established interventional cardiology networks and steady adoption of drug-coated balloon procedures, though uptake varies by country due to reimbursement and budget differences.

Asia-Pacific accounted for 24.0% (USD 38.4 million) in 2025 and is the fastest-growing region, expected to reach USD 78.3 million by 2032 at a 10.7% CAGR. Expansion is driven by rising PCI volumes, improved access to advanced devices, and local manufacturing, including OrbusNeich’s China-developed scoring balloon platform.

Latin America held 5.0% (USD 8.0 million) in 2025 and is projected to reach USD 12.2 million by 2032, with growth concentrated in major urban hospitals due to limited access to advanced PCI tools.

The Middle East & Africa accounted for 4.0% (USD 6.4 million) in 2025 and is expected to reach USD 9.5 million by 2032, with demand mainly limited to well-equipped referral centers and uneven regional access to specialist devices.

 

Future Trajectory: From Lesion Preparation to Precision-Driven PCI Ecosystems

Coronary scoring balloons will gain importance through preparation of calcified lesions, treatment of in-stent restenosis and preparation for drug-coated balloon therapy. Growth will favour devices combining effective scoring with reliable delivery through narrow, tortuous arteries.

The market’s main constraint is the widening choice of competing technologies. Hospitals can select high-pressure balloons, cutting balloons, atherectomy or intravascular lithotripsy depending on calcium depth, lesion length, vessel anatomy, available imaging and physician experience. Scoring balloons will therefore expand as a targeted component of complex PCI rather than becoming the default option for every calcified artery.

 

Coronary Scoring Balloons Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 160 Million
Revenue Forecast in 2032	USD 270 Million
Overall Growth Rate	CAGR of 7.8% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Balloon Type, By Lesion Type, By End User, By Geography
By Balloon Type	Semi-Compliant Scoring Balloons, Non-Compliant Scoring Balloons
By Lesion Type	Calcified Lesions, Fibrotic Lesions, In-Stent Restenosis, Ostial and Bifurcation Lesions, Other Complex Coronary Lesions
By End User	Hospitals, Cardiac Catheterization Laboratories, Ambulatory Surgical Centers, Specialty Cardiac Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising treatment volumes for calcified and fibrotic coronary lesions. Increasing use of scoring balloons in in-stent restenosis procedures. Expanding adoption of drug-coated balloons that require controlled lesion preparation. Growing preference for lower-complexity plaque-modification tools before stenting or DCB delivery.
Customization Option	Available upon request